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1. Introduction  
There has been a worldwide epidemic increasing in the prevalence of sedentary, overweight 
and obesity that comes with modernity and urbanization (Wang et al., 2002). The 
consequence is the development of insulin resistance (IR) and type 2 diabetes (T2D). This is 
classically defined as a metabolic disease that occurs due to a higher IR that leads to a slow 
setting of lower insulin production (more relative than absolute), in general in adult age. 
T2D is associated also with a genetic predisposition. The majority of T2D individuals are 
overweight or obese and the ones who do not, at least present increased abdominal adipose 
mass (ADA, 1997). The rising prevalence of overweight and obesity is happening also in 
children and adolescents (Pinhas-Hamiel et al., 1996; Willi & Egede, 2000; Rosenbloom et 
al., 1999). The metabolic syndrome (MS), which physiopathology is based on IR, shows the 
same trend in children and adolescents (Jago et al., 2008), as well as isolated pre-diabetes (Li 
et al., 2009).  
In parallel, it has been seen an elevation in the number of type 1 diabetes (T1D) cases and its 
establishment at a younger age (EURODIAB ACE Study Group, 2000). T1D is characterized 
primarily by a pancreatic beta cell destruction, which may lead to ketosis. It can be classified 
as autoimmune (with positive anti-islet, anti-insulin, anti-GAD, anti-IA2 and/or anti-IA2 
beta antibodies) or idiopathic, in which no autoantibodies can be detected, and occurs more 
frequently in individuals of African-American or Asian origin. Multiple genetic 
predisposition and environmental factors are involved with T1D (ADA, 1997). At least one 
of those autoantibodies is present in 85-90% of T1D on diagnosis. The treatment for T1D 
consists of multiple insulin injections, known as intensive treatment, to obtain adequate 
glycemic control and therefore prevent micro (The DCCT Research Group, 1993) and 
macrovascular (Nathan et al., 2005 and 2003) chronic complications. However, it can be 
followed by weight gain most of the times (Arai et al., 2008), which can amplify the risk of 
cardiovascular disease (CVD) in spite of good glycemic control. This weight gain can start 
on puberty and persist along adulthood (Särnblad et al., 2007). Therefore, some of these 
patients present clinical features of both T1D and T2D, confounding its classification. This 
phenotype was initially called double diabetes (DD) (Libman & Becker, 2003; Becker et al., 
www.intechopen.com
 
Type 1 Diabetes – Complications, Pathogenesis, and Alternative Treatments 182 
2001), and is characterized by positive pancreatic autoantibodies in patients with clinical 
features of T2D, as IR and overweight and/or obesity (Pozzilli & Buzzetti, 2007; Gilliam et 
al., 2005; Reinehr et al., 2006), as shown in Table 1 (Pozzilli & Buzzetti, 2007) and in Figure 1. 
 
 T1D DD T2D 
Age at disease 
onset 
Childhood +++ 
Adolescence +++ 
Adult + 
Childhood ++ 
Adolescence ++ 
Adult (LADA) + 
Childhood + 
Adolescence ++ 
Adult +++ 
Major genetics 
predisposition 
MHC class I and II, 
InsVNTR, CTLA-4, 
PTPN22 
? 
APM1, PPARγ 2, 
PtdCho-1, TCF7L2 
 
Environmental 
factors 
Diet, viruses 
Cow´s milk in infancy 
Life style (diet, 
sedentary life) 
Life style (diet, 
sedentary life) 
Circulating 
antibodies to β 
cells 
+++ + - 
T cell-mediated 
immunity to β 
cells 
+++ ++ - 
C-peptide 
secretion - + +++ 
IR -/+ ++ +++ 
Inflammatory 
markers 
(cytokines, 
adipokines) 
+ ++ +++ 
Macrovascular 
complications + ++ +++ 
Table 1. Clinical and pathogenic features of DD compared to T1D and T2D (Pozzilli & 
Buzzetti, 2007). 
 
 
 
Fig. 1. Schematic representation showing where DD lies in respect to age and the two types 
of diabetes, as illustrated by two ‘rainbows’ (Pozzilli & Buzzetti, 2007). 
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2. Obesity as a accelerate factor to type 1 diabetes mellitus development 
Studies with streptozotocin-induced diabetic baboons showed that to have an abnormal 
glucose tolerance it is necessary an isolated huge loss of beta-cell mass or a moderate loss of 
these cells associated to an IR (McCulloch et al., 1991), that could be in humans the 
physiologically IR of adolescence (Acerini et al., 2000) or gestation (Buschard et al., 1987), 
periods with higher incidence of T1D, or pathological situations like infection (usually one 
of the triggering factors of T1D) or weight gain.  
Others studies suggest that the increase in the  body mass index (BMI) and the consequent 
IR may accelerate the β cell destruction process in individuals predisposed to T1D, due to 
the release of obesity-related cytokines that show inflammatory and/or immunomodulatory 
properties (Aldhahi & Hamdy, 2003), triggering diabetes. This hypothesis may be reinforced   
by one study that correlated high anti-GAD levels with high BMI (Rolandsson et al., 1999). 
Two interesting data from studies with non-obese diabetic (NOD) mice are that 
hyperinsulinemia, an IR marker, precede clinical T1D (Armani et al., 1998) and that T1D 
incidence falls after treatment with rosiglitazone, an insulin sensitizer drug (Beales & 
Pozzili, 2002). 
The IR, autoimmunity and apoptosis of the β cells constitutes the three factors of the called 
“accelerator hypothesis”, proposed by Wilkin (Wilkin, 2001), that contemplate the factors 
presented in both more common types of diabetes, that is, T2D and T1D. There is a 
constitucional (intrinsic) high speed of apoptosis of β cells that is necessary to the 
development of diabetes, but rarely enough. The other two factors, extrinsic, that can speed 
the apoptosis of beta-cells are IR (result of weight gain and/or physical inactivity) and 
autoimmunity against beta-cells. 
It is known that obese individuals have elevated serum levels of leptin, a cytokine secreted 
by adipocytes in proportion to adipose tissue mass and that is responsible, among other 
functions, for regulating food intake and thus BMI. Moreover, leptin controls the cellular 
immune response and is involved in the pathogenesis of autoimmune diseases (Lord, 2002). 
Studies have shown that administration of leptin in NOD mice promoted an early 
inflammatory infiltrate in the pancreatic islets, increased production of interferon gamma 
(IFN-gamma) by T lymphocytes, which accelerated the establishment of a T1D (Matarese, 
2002 e 2005). 
On the other hand, adiponectin, another important cytokine produced by adipose tissue, 
inversely proportional to its fat mass, can decrease the systemic and pancreatic islets 
inflammatory process, acting as a protective factor in the development of T1D, in addition to 
reducing IR (Kadowaki et al., 2006; Wellen & Hotamisligil, 2005). 
However, development report (OECD, 2009) from 16 countries does not show any obvious 
relationship between national estimates of childhood obesity prevalence and incidence rates 
of T1D (Table 2). Therefore, obesity does not account for the wide between-country 
differences in T1D incidence, which range from 0.57 per 100 000 person-years in China to 
more than 48 per 100 000 person-years in Sardinia and Finland in the 0- to 14-year age group 
(Daneman, 2006). 
On the other hand, in a meta-analysis of nine studies (eight case–control studies and one 
cohort study) comprising a total of 2658 cases (Verbeeten et al., 2011), seven reported a 
significant association between childhood obesity, BMI or %weight-for-height and increased 
risk for T1D. Four of these studies reported childhood obesity as a categorical exposure and 
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produced a pooled odds ratio of 2.03 (95% CI 1.46–2.80) for subsequent T1D, but with age at 
obesity assessment varying from age 1 to 12 years (Figure 2). A dose–response relationship 
was supported by a continuous association between childhood BMI and subsequent T1D in 
a meta-analysis of five studies (pooled odds ratio 1.25 (95%CI 1.04–1.51) per 1 SD higher 
BMI) (Figure 3). 
 
Country T1D incidence rate in children aged 0-14 
years (per 100.000 person-years) 
% of children aged 11-15 
years overweight or obese 
Finland 57,4 15,8 
Sweden 41 10,5 
Norway 27,9 10 
UK 24,5 12 
Denmark 22,2 9,7 
Canada 21,7 21,3 
USA 20,8 29,8 
Netherlands 18,8 8 
Germany 18 12 
Ireland 16,3 14,2 
Iceland 14,7 14,5 
Spain 13 16,7 
Poland 12,9 11,2 
France 12,2  10,5 
Greece 9,9 18,8 
Italy 8,4 18,3 
Table 2. Relationship between Type 1 diabetes incidence and prevalence of childhood 
overweight or obesity in 16 Organization for Economic Co-Operation and Development 
(OECD) countries, from Health at a Glance 2009: OECD Indicators (OECD, 2009). 
 
 
Fig. 2. Meta-analysis (fixed-effects inverse variance model) of studies of childhood obesity as 
a risk factor for subsequent T1D (Verbeeten et al., 2011). 
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Fig. 3. Meta-analysis (random-effects inverse variance model) of studies of childhood BMI as 
a risk factor for subsequent T1D. Odds ratios correspond to a 1-unit increase in BMI 
standard deviation score (SDS)(Verbeeten et al., 2011). 
3. Obesity after clinical Type 1 diabetes diagnostic 
If on one hand intensive insulin prevents microvascular and macrovascular complications 
associated with poor glycemic control, the other brings an increased risk of severe 
hypoglycemia and weight gain, traditionally viewed as a normalization of weight, i.e. the 
correction of glycosuria, diuresis, and wasting with the initiation of insulin therapy. Insulin 
stimulates lipogenesis, inhibits protein catabolism, and slows basal metabolism. Other 
important aspect is the abnormal physiological route of insulin via its peripheral 
administration in those with T1D, which is also associated with reduced energy metabolism 
(Charlton & Nair, 1998). Classically normal or underweight, the phenotype of the T1D 
individuals is thus changing. A follow-up of 18 years of 589 individuals from the Pittsburgh 
Epidemiology of Diabetes Complications Study (EDC), a cohort of childhood-onset T1D,  
showed an increase in the prevalence of overweight by 47% (from 28.6% at baseline to 42%) 
and of obesity by sevenfold (from 3.4% at baseline to 22.7%), concomitantly with the highest 
prevalence of intensive insulin therapy - 7% and 82% were on intensive insulin therapy (≥ 3 
insulin injections per day or on insulin pump) at baseline and 18 years after, respectively 
(Conway et al., 2010). Although injection frequency increased, total daily insulin dose 
decreased from 0.76 to 0.62 U⁄kg⁄day. Figure 4 shows the temporal patterns in the prevalence 
of being overweight and obese and the use of intensive insulin treatment, and these data 
was not influenced by the aging of the cohort and survivorship, as can be seen on Table 3. 
(age-group-specific prevalence for the 40–49-year-old age group by time period): overweight 
or obesity were present in 25% of the T1D individuals in 1986–1988 and in 68.2% in 2004–
2007 (Conway et al., 2010). 
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Fig. 4. Temporal patterns in overweight and obesity in Type 1 diabetes (Conway et al., 2010). 
 
 BMI < 20 kg⁄m2 
(underweight) 
 
20 ≤ BMI < 25 
kg⁄m2 (normal 
weight) 
25 ≤ BMI < 30 
kg⁄m2 
(overweight) 
BMI ≥ 30 kg⁄m2 
(obese) 
1986–1988    
 
4 (9.1) 29 (65.9) 10 (22.7) 1 (2.3) 
1988–1990     
 
3 (5.8) 29 (55.8) 17 (32.7) 3 (5.8) 
1990–1992    
 
6 (8.5) 43 (60.6) 18 (25.4) 4 (5.6) 
1992–1994     
 
10 (12.2) 39 (47.6) 27 (32.9) 6 (7.3) 
1994–1996     
 
14 (11.9) 58 (49.2) 35 (29.7) 11 (9.3) 
2004–2007    
  
5 (2.9) 50 (28.9) 79 (45.7) 39 (22.5) 
Table 3. Age-specific prevalence of underweight, normal weight, overweight, and obese for 
those aged 40-49 years in each time period, n (%)(Conway et al., 2010) 
www.intechopen.com
 
Obesity in the Natural History of Type 1 Diabetes Mellitus: Causes and Consequences 187 
The prevalence of overweight/obesity in this T1D population was lower at baseline than 
general population (31.9 vs. 55.9%), although the incidence in both was similar after a mean 
of 7 years’ follow-up (12%), and after 18 years’ follow-up the prevalence of overweight in 
T1D people appear to have increased at a faster pace than in the general population. 
Predictors of weight change were a higher baseline HbA1c, symptomatic autonomic 
neuropathy (inversely), overt nephropathy (inversely), and going onto intensive insulin 
therapy during follow-up. By the end of this study, 24% of the T1D people had died. Thus, 
as overt nephropathy and symptomatic autonomic neuropathy are associated with weight 
loss, the survivors are biased toward weight gain. The EDC Study also showed that, in T1D 
with a higher baseline HbA1c, moderate weight gain did not adversely affect the 
cardiovascular risk profile and favorably influenced the lipid profile in the setting of 
ameliorated glycemic control, but increased LDL cholesterol levels in the absence of a major 
improvement in glycemic control (Williams et al., 1999). Subjects who gained the least 
weight had the lowest LDL cholesterol levels at the follow-up period regardless of changes 
in HbA1 category. But when the weight gain after insulin was great, case of part of the 
patients who received intensive treatment in the Diabetes control and complications trial 
(DCCT) study and placed in the highest quartile of change in BMI, there was unmasking of 
central obesity or even MS in T1D (Purnell et al, 1998). These patients gained an average of 
14 kg during the course of the study, about twice the weight gain equivalent to the third 
quartile of intensive care and the last quartile of patients on conventional treatment. Patients 
with the highest weight gain had the highest values of waist-hip ratio, blood pressure and 
insulin requirements when compared to the group with the same degree of glycemic control 
and also in intensive care, but who did not gain much weight. These youngsters also had a 
relatively atherogenic lipid profile, with elevations to levels of triglyceride, LDL cholesterol 
and apolipoprotein B (apoB) compared to their peers, also intensively treated, but without 
similar weight gain. The DCCT study (Purnell et al., 2003) also showed that the presence of 
family history of T2D was one of the strongest predictors for the weight gain in individuals 
with T1D who underwent intensive insulin therapy in the DCCT. In individuals with a 
family history of T2D, the weight gain, the final weight, the central fat distribution assessed 
by waist circumference, the insulin dose (units/kg/day) and degree of dyslipidemia were 
higher than in those without history familial T2D. Dyslipidemia included increases in 
triglycerides (TG) in VLDL particles and IDL (intermediate-density lipoprotein), which 
changes are common in individuals with central adiposity (Terry et al., 1989) and T2D 
(Brunzell & Chait, 1997). This could correspond to the expression of genes predisposing to 
T2D in this population. The findings of this study support the hypothesis that insulin 
treatment allows the expression of various components of MS in individuals with T1D who 
have family history of T2D, but also suggests that this group should be monitored more 
closely and earlier in relation to their potential of developing macrovascular complications, 
which is responsible for most of the increase in mortality found in patients with T1D (Laing 
et al., 1999), more than three times the general population. 
4. Type 1 diabetes and Metabolic Syndrome 
The insulin resistance is  a soil to MS development and it is present during T1D evolution, 
even because of weight gain or because of the glucotoxicity – there was shown a proportion 
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between  fasting  glycemic and IR, and improvement of glycemic control is linked to better 
insulin sensitivity, for example contributing to the so-called period of "honeymoon", the 
remission phase of diabetes, well known by clinicians, and may occur in up to 50% of 
patients during the first year of disease (DCCT Research Group, 1987). Yki-Jarvinen et al. 
(1986), studied insulin sensitivity using the hyperinsulinemic euglycemic clamp in 15 adult 
patients with T1D and normal BMI during the first 2 weeks, 3 months and 1 year after 
clinical diagnosis. In the first two weeks of diagnosis, they had a decrease in insulin 
sensitivity when compared to controls. However, three months after diagnosis, there was an 
improvement in insulin sensitivity in these patients, and it became similar to that of 
controls. Importantly, this improvement in insulin sensitivity coincided with the period of 
"honeymoon" in these patients, and showed a good correlation with HbA1c values and 
insulin doses in the treatment. Insulin sensitivity of patients who entered clinical remission 
was 40% greater than those who did not have this condition. Recently, our group performed 
a cohort and multicenter study (Gabbay et al, 2005; Dib, 2006) to determine the prevalence of 
MS in a group of patients with T1D and assessing their relation with the time of diagnosis. 
The study included 524 (276 females) T1D (according to the criteria of the Brazilian Diabetes 
Society and American Diabetes Association) with an average age of 20 ± 9 years and divided 
according to the time of T1D in 4 groups: GI, ≤ 5 years (n = 264), G-II, 6-10 years (n = 108), G 
III, 11-15 years (n = 96) and G IV,> 15 years (n = 56). In these groups were analyzed BMI 
(kg/m2), total daily doses of insulin for treatment (U/kg/day), HbA1c values and the 
prevalence of MS. The criterion used for characterization of MS was the one of the World 
Health Organization, that is, diabetes mellitus and 2 or more of the following: increase in 
waist circumference (criterion set for youth) (Freedman et al., 1999), TG ≥ 150 mg/dL or 
HDL-C < 40 mg/dL (males) and < 50 mg/dL (females), urinary albumin excretion (≥ 20 
µg/min) and hypertension (according to criteria adjusted for age and sex) (Brazilian 
Hypertension, Heart and Nephrology , Societies 2002). The daily insulin dose and HbA1c 
values were significantly lower in G-I than in other groups (G-I: 0.7 ± 0.3, G-II: 1.1 ± 0.3, G-
III: 1.0 ± 0.3 and G-IV: 0.8 ± 0.2 U/kg/day, p = 0.000) and (G-I: 8.7 ± 2.6, G-II: 9.5 ± 2.2, G-III, 
9.5 ± 2.3 and G-IV: 9.4 ± 2.8%, p = 0.000), respectively. There was a significant increase in the 
values of waist circumference (G-I: 71.9 ± 2.2, G-II: 75.7 ± 11.1, G-III: 76.5 ± 8.4 and G-IV: 80.2 
± 7.5 cm, p = 0.000) and BMI (G-I: 20.6 ± 3.8, G-II: 22.4 ± 3.6, G-III: 22.5 ± 3.1 and G- IV: 23.1 ± 
4.1 kg/m2, p = 0.000) after 5 years of diagnosis of T1D. However, it is important to note that 
the BMI values were not superior to classical criteria of obesity or even overweight. The 
prevalence of MS (G-I: 5.1, G-II: 11.2, G-III: 18.9 and G-IV, 31.5%, p = 0.000) increased with 
time of diagnosis (Figure 5). The odds ratio (OR) for the development of MS in the other 
groups in relation to G-I was significant G-III onwards, being equal to 3.59 and 7.18 for this 
for G-IV in relation to G-I, both with p = 0.001. That is, the odds for the development of MS 
in patients with T1D and over 15 years of diagnosis is 618% higher than under 5 years of 
disease. Similarly, the odds for the development of MS for patients with T1D between 11 
and 15 years duration is 259% higher than those with less than 5 disease in this group of 
patients. Other factors related to insulin resistance, such as visceral fat, BMI and TG, even 
when considered separately, also increased with the duration of the disease. 
In another study (Giuffrida et al., 2005), 500 T1D patients [age 19.7 ± 8.9 years (mean ± SD), 
52% female], we observe that, also analyzed separately, the prevalence of microalbuminuria 
(GI: 24.1%, G-II, 25.0%, G-III: 31.0% and G-IV: 55.6%, p <0.05) and hypertension (GI, 8.3%; 
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G-II: 13.6%, G-III: 28.6% and G-IV: 44.4%, p = 0.000) increased with duration of disease. Data 
from these studies suggest that chronic glucotoxicity (elevated HbA1c) and factors involved 
in diabetic nephropathy (microalbuminuria and hypertension) may be one of the 
mechanisms for the development of MS in T1D, among many others. 
 
 
                                                                                               Duration of Type 1 Diabetes 
Fig. 5. Prevalence of MS in patients with T1D, according to disease duration. (Dib, 2006) 
Aiming to compare the prevalence of MS using the ATP III criteria modified for age in our 
group of T1D, we studied 521 (51.2% female, age 20 ± 9 years; time of diagnosis of diabetes: 
7.7 ± 6.9 years and HbA1c: 9.0 ± 2.4%) and found that this was equal to 12% (unpublished 
data). 
The lowest concentration in the insulin in the liver causes a decrease in the synthesis of 
GHBP levels (Growth Hormone Binding Protein) (Bereket et al., 1999) that leads to a 
decrease in GH action, in the values of IGF-1 and in the inhibitory counter-regulation of this 
hormone, resulting in an exaggerated secretion of GH and increased insulin resistance. 
The realization of a strict glycemic control in T1D, according to current guidelines, many 
often leads to use of supraphysiological doses of insulin, which could result in a stimulation 
of androgen synthesis, mediated by insulin, as occurs in cases of insulin resistance. 
Accordingly, the prevalence of Polycystic Ovary Syndrome (PCOS) and other symptoms 
and signs of hyperandrogenism were evaluated in a group of 85 patients with T1D (Escobar-
Morreale et al., 2000). PCOS was defined by the presence of menstrual changes and clinical 
or laboratory evidence of hyperandrogenism. Other causes of elevated androgen hormones 
were excluded. Eighteen normal eumenorrheic women served as controls. Thirty-three 
patients (38%) presented with T1D changes associated with an androgen excess (16 with 
PCOS and 17 with hirsutism without menstrual abnormalities). The patients with T1D and 
PCOS had elevated total and free testosterone and androstenedione but normal levels of 
sex-hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate (DHEAS). 
However, despite the finding of a high prevalence of hyperandrogenism (including PCOS 
and hirsutism), there was no difference between clinical variables such as duration of 
Prevalence 
(%) 
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diabetes, age at diagnosis, conventional or intensive insulin treatment, average daily dose of 
insulin or glucose control between the T1D patients with and without hyperandrogenism in 
study. 
The gold-standard method for evaluating IR is the hyperinsulinemic euglycemic clamp 
that directly measures the relationship between blood glucose and insulin levels, but it is 
difficult to be executed on a large scale since it is an invasive and expensive procedure. 
For this reason, HOMA-IR is used as a surrogate method to indirectly measure IR, 
calculated through fasting glycemia and insulinemia relationship. On the other hand, this 
calculation cannot be used for T1D as these patients do not produce endogenous insulin. 
So to evaluate the insulin sensitivity in these patients   eGDR calculation (Equation 1) was 
developed that shown   a good correlation with hyperinsulinemic euglycemic clamp 
(Chillarón et al., 2008): 
 eGDR (mg.kg-1.min-1) = 24,4 – 12,97 (W/H) – 3,39 (Hypertension) – 0,60 (HbA1c) (E1) 
In which W/H is the waist-hip ratio(cm), hypertension is the presence or absence of 
hypertension (0 = no and 1 = yes) and the value of HbA1c is represented in %. It is also a 
good predictor of mortality, coronary arterial disease (CAD), microalbuminuria - a 
precocious hallmark of endothelial dysfunction (Pambianco et al., 2007) – and MS for T1D 
individuals, according to IDF (International Diabetes Federation), WHO (World Health 
Organization) and NCEP/ATPIII modified by AHA (American Heart Association). 
As we know the insulin resistance is linked to an ectopic store of fat in insulin sensitive 
tissues like liver and muscle, but it is not clear if this fat accumulation leads to a 
hyperinsulinemic state or if it is its consequence.  In a study with T2D patients, the 
glycemic control obtained after 67 hours of insulin treatment caused an accrual in 
intramyocellular and intrahepatic lipid content measured by nuclear magnetic resonance 
(NMR) spectroscopy, without compromising insulin sensitivity (Anderwald et al., 2002). 
Like T2D individuals, the intramyocellular lipid content in T1D ones was increased 
compared to controls and there was a direct relation with the glycemic control (Sibley et 
al., 2003). 
There has been also noted a clear association between IR and visceral fat store, that can take 
its content extended in consequence of intensive insulin treatment independently of the type 
of diabetes, aggravating the CVD risk. In the DCCT study, the subgroup of T1D individuals 
that received intensive insulin treatment had a higher growth in BMI compared to the ones 
who were treated conventionally and it was noted a stronger correlation of this BMI 
variation with visceral fat deposit than with subcutaneous fat (Sibley et al., 2003). In this 
study, there are also demonstrations of direct association between visceral fat content and 
hepatic lipase, which favors the emergence of atherogenic dyslipidemia in these intensive 
treated individuals that put on more weight, reaching lipid levels similar to those of the 
conventionally treated group, suggesting loss of the benefits of intensive insulin therapy on 
lipids in this group of patients who had an excessive weight gain. 
In other study (Nadeau et al., 2010), lean T1D adolescents with short time of disease 
(average of 7.5 years) without any inflammatory, clinical or lipid abnormalities  had a IR - 
measured by hyperinsulinemic euglycemic clamp - similar to non diabetic obese adolescents 
and a superior IR than control subjects matched for age, pubertal stage, physical activity 
level and BMI, despite normal waist and intramyocellular lipid content. 
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There was also a demonstrated association between fat mass and blood pressure levels in 
T1D children and adolescents – high fat content, identified by the bioimpedance (BIA), 
and BMI were related to higher systolic and diastolic blood pressure (Pietrzak et al., 2009). 
The BIA is an easy, noninvasive, portable, no risk, relatively inexpensive method to 
measure the percentage of fat and provides results comparable to dual energy X-ray 
absorptiometry (DXA) (Elberg et al., 2004; Völgyi et al., 2008), that is reliable but 
expensive, requiring trained operators, individuals exposed to ionizing radiation and is 
not portable (Thomson et al., 2007). 
There are data indicating good correlation between BIA and DXA, including Brazilian 
(Braulio et al., 2010) and T1D subjects (Leiter et al., 1994). Although overestimating the 
percentage of fat in lean individuals and underestimate it in obese (Sun et al., 2005), proves 
useful for predicting metabolic risk (including IR) as well as BMI and waist circumference 
(Lee et al., 2008). Through the BIA, it is possible to calculate the CDI (central fat distribution 
index), which assesses the impact of subcutaneous fat in the central fat distribution, and can 
be measured by dividing the area of abdominal subcutaneous fat mass by total fat (Silva et 
al., 2009). This measure seems to be relevant in that, according to some studies (Silva et al., 
2009; Van Harmelen et al., 1998), the main source of leptin is the abdominal subcutaneous 
adipose tissue, either by mass effect - the subcutaneous adipose tissue is the major fat depot 
- as to produce more leptin (larger cell size and leptin gene expression) that omental adipose 
tissue. However, depending on the impedance (eg the trunk), the results may vary 
according to position changes, skin temperature, variation in electrode impedance and 
errors in their placement (Scharfetter et al., 2001). 
A new adipokine identified visfatin, increases in proportion to visceral fat mass (Fukuhara 
et al., 2005) and decreases after gastric band placement (Haider et al., 2006). It is high in 
individuals with T2D (Chen et al., 2006) and even more in T1D (López-Bermejo et al., 2006), 
suggesting that its rising is linked to deterioration of pancreatic β cells. In vitro, visfatin 
activates the insulin receptor regardless of fasting state, increasing glucose uptake in muscle 
and adipose tissue and reducing hepatic glucose production independently of insulin levels 
(Fukuhara et al., 2005). 
Hyperhomocysteinemia, known risk factor for coronary atherosclerosis (Okada et al., 1999), 
has also been shown to be detrimental to pancreatic insulin secretion (Patterson et al., 2006). 
The C-reactive protein (CRP), an inflammatory marker that confers increased risk for 
atherosclerosis (Hayaishi-Okano et al., 2002), is increased in T2D patients (Nabipour et al., 
2008) and obese subjects (Richardson et al., 2009), and also relates to the control of diabetes 
(King et al., 2003), i.e. may increase due to the weight gain caused by intensive control of 
diabetes (Schaumberg et al., 2005). 
Ferritin is another acute phase inflammatory marker, correlate positively with CRP and BMI 
(Richardson et al., 2009), and also more specifically with visceral adiposity and insulin 
resistance (Iwasaki et al., 2005), leading to increased ferritin levels in T2D patients, 
concurrent with an augmentation of visfatin (Fernandez-Real et al., 2007). 
Recently, several studies have indicated that the gene associated with fat mass and BMI 
(FTO) has an important genetic effect on BMI and risk of obesity through the rs9939609 
polymorphism. This polymorphism is linked to an impaired responsiveness to satiety, ie 
have an effect on appetite (Wardle et al., 2008). The homozygous AA genotype results in an 
average gain of 3 kg or 1 unit of BMI over the TT genotype. There is evidence that this 
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polymorphism is linked to BMI gain in subjects with T1D (Gu et al., 2010) and higher levels 
of leptin and CRP (Welsh et al., 2010). 
5. Conclusion 
Obesity may both contribute to the onset of T1D as being a consequence of intensive 
treatment with insulin, that is, good glycemic control in T1D can lead to excessive weight 
gain in predisposed individuals (eg relatives of T2D), IR and consequently MS. Thus, the 
current approach of patients T1D should happen as it is done in T2D, multifactorial with an 
early and intensive monitoring of lifestyle, blood glucose, blood pressure and lipids, with 
the aim of identifying, correcting these factors and potentially reduce the high risk for 
cardiovascular disease in these patients. So gain weight can accelerate the presentation  and 
modify the initial TID phenotype  as increase the cardiovascular risk  factors during 
evolution do the disease .  
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